New stem cell transplant could reduce immune suppression in bone marrow failure patients

NCT ID NCT03579875

Recruiting now Disease control Sponsor: Masonic Cancer Center, University of Minnesota Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a special stem cell transplant for people with inherited bone marrow failure disorders like Fanconi anemia. The transplant uses a technique to remove certain immune cells, aiming to reduce the need for long-term immune-suppressing drugs and lower infection risk. Up to 48 participants will receive the transplant and be monitored for complications and recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: stem cell transplant with T cell depletion
What this could lead to: If successful, this approach could offer a safer transplant option for people with inherited bone marrow failure, reducing the need for long-term immune-suppressing drugs and lowering infection risk.
What could go wrong: This is an early phase 2 trial with only 48 participants, so results may not apply to everyone. There are still risks of graft failure, infection, and other transplant complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BONE MARROW FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired aplastic anemia aplastic anemia Bone Marrow Failure Disorders bone marrow failure syndrome dyskeratosis congenita Fanconi anemia myelodysplastic syndrome Myelodysplastic Syndromes TCR-alpha-beta-positive T-cell deficiency telomere syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BONE MARROW FAILURE DYSKERATOSIS CONGENITA FANCONI ANEMIA MYELODYSPLASTIC SYNDROMES SEVERE APLASTIC ANEMIA T CELL RECEPTOR ALPHA/BETA DEPLETION TELOMERE BIOLOGY DISORDER TELOMERE BIOLOGY DISORDERS

Contacts and locations

Locations

Masonic Cancer Center at University of Minnesota
RECRUITING

Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.